Comparative Pharmacology
Head-to-head clinical analysis: DRAX EXAMETAZIME versus GLOFIL 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAX EXAMETAZIME versus GLOFIL 125.
DRAX EXAMETAZIME vs GLOFIL-125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAX EXAMETAZIME is a diagnostic radiopharmaceutical composed of technetium-99m (Tc-99m) labeled to exametazime (hexamethylpropyleneamine oxime, HMPAO). It passively diffuses across the blood-brain barrier and is rapidly converted to a hydrophilic complex, which is trapped in brain tissue. Distribution is proportional to regional cerebral blood flow, allowing SPECT imaging of cerebral perfusion.
GLOFIL-125 (pentoxifylline) is a xanthine derivative that improves erythrocyte flexibility by inhibiting phosphodiesterase, leading to increased intracellular cAMP. It also reduces blood viscosity and platelet aggregation, improving microcirculation.
Adult: 5-20 mCi (185-740 MBq) administered intravenously as a single dose for brain imaging; dose is based on patient weight and imaging protocol.
125 mg orally twice daily.
None Documented
None Documented
Terminal half-life is 6-8 hours; clinical context: allows for daily dosing in imaging studies.
Terminal elimination half-life: 2.5–3.5 hours (prolonged in renal impairment; up to 20–30 hours in severe chronic kidney disease).
Renal: 50-65% unchanged; fecal: 35-50% as metabolites; total renal elimination accounts for ~70% of dose, with 30% undergoing biliary excretion.
Renal excretion of unchanged drug >90%; biliary/fecal <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical